FDA has approved Taltz (ixekizumab) use in Active Ankylosing Spondylitis (Axial Spondyloarthritis). IXE previously approved for psoriasis & PsA. Recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. https://t.co/S8zwuYuK2H
Links:
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of A…
https://buff.ly/2MDDH3U
Aug-26-2019
